Thermo Fisher Scientific Inc (NYSE:TMO) Director Jim P. Manzi sold 1,000 shares of Thermo Fisher Scientific stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $175.20, for a total value of $175,200.00. Following the completion of the sale, the director now directly owns 38,757 shares of the company’s stock, valued at $6,790,226.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Thermo Fisher Scientific Inc (NYSE TMO) traded down 0.19% during mid-day trading on Friday, reaching $172.57. The company’s stock had a trading volume of 1,182,702 shares. The firm has a market capitalization of $67.32 billion, a PE ratio of 30.06 and a beta of 1.06. The firm has a 50-day moving average of $176.75 and a 200-day moving average of $166.35. Thermo Fisher Scientific Inc has a 52 week low of $139.07 and a 52 week high of $182.87.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.03. The company had revenue of $5 billion during the quarter, compared to the consensus estimate of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The company’s revenue was up 10.2% on a year-over-year basis. During the same period last year, the firm earned $2.03 earnings per share. Equities research analysts forecast that Thermo Fisher Scientific Inc will post $9.24 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be paid a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.35%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.45%.

WARNING: “Thermo Fisher Scientific Inc (TMO) Director Sells $175,200.00 in Stock” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/08/18/thermo-fisher-scientific-inc-tmo-director-sells-175200-00-in-stock.html.

A number of brokerages have recently weighed in on TMO. Bank of America Corporation lifted their price objective on Thermo Fisher Scientific from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, May 9th. Cleveland Research raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. Jefferies Group LLC lifted their price objective on Thermo Fisher Scientific from $160.00 to $175.00 and gave the company a “hold” rating in a research note on Friday, April 28th. BidaskClub cut Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 27th. Finally, Citigroup Inc. reaffirmed a “buy” rating and issued a $201.00 price objective (up from $182.00) on shares of Thermo Fisher Scientific in a research note on Monday, July 10th. One analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $188.56.

Hedge funds have recently made changes to their positions in the stock. Toronto Dominion Bank increased its stake in shares of Thermo Fisher Scientific by 25.4% in the second quarter. Toronto Dominion Bank now owns 134,277 shares of the medical research company’s stock valued at $23,424,000 after buying an additional 27,178 shares in the last quarter. Advisory Services Network LLC increased its stake in shares of Thermo Fisher Scientific by 13.9% in the second quarter. Advisory Services Network LLC now owns 7,850 shares of the medical research company’s stock valued at $1,370,000 after buying an additional 957 shares in the last quarter. Beaton Management Co. Inc. acquired a new stake in shares of Thermo Fisher Scientific during the second quarter valued at $1,256,000. WINTON GROUP Ltd increased its stake in shares of Thermo Fisher Scientific by 5,332.5% in the second quarter. WINTON GROUP Ltd now owns 94,036 shares of the medical research company’s stock valued at $16,406,000 after buying an additional 92,305 shares in the last quarter. Finally, Millie Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 0.4% in the second quarter. Millie Capital Management LLC now owns 19,149 shares of the medical research company’s stock valued at $3,341,000 after buying an additional 75 shares in the last quarter. Institutional investors own 87.60% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.